Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18933687 | GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES | October 2024 | June 2025 | Allow | 7 | 2 | 0 | No | No |
| 18895296 | IMMUNE CELLS DEFECTIVE FOR SUV39H1 | September 2024 | April 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 18886134 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | September 2024 | December 2024 | Allow | 3 | 1 | 0 | No | No |
| 18820652 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | March 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18821068 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18820609 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18821057 | DELIVERY AND FORMULATION OF ENGINEERED NUCLEIC ACIDS | August 2024 | February 2025 | Allow | 6 | 1 | 0 | No | No |
| 18796740 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | August 2024 | December 2024 | Allow | 4 | 1 | 0 | No | No |
| 18777787 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | July 2024 | February 2025 | Allow | 7 | 1 | 0 | No | No |
| 18777187 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | July 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18773146 | COMPOSITION FOR REGULATING PRODUCTION OF PROTEINS | July 2024 | January 2025 | Allow | 6 | 1 | 0 | No | No |
| 18757141 | AAV CAPSID VARIANTS AND USES THEREOF | June 2024 | March 2025 | Allow | 8 | 1 | 1 | No | No |
| 18649317 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | April 2024 | November 2024 | Allow | 6 | 1 | 0 | No | No |
| 18620748 | Use of CD2/5/7 Knock-Out Anti-CD2/5/7 Chimeric Antigen Receptor T cells Against T Cell Lymphomas and Leukemias | March 2024 | October 2024 | Allow | 7 | 2 | 0 | Yes | No |
| 18596451 | VACCINATION WITH mRNA-CODED ANTIGENS | March 2024 | May 2024 | Allow | 2 | 1 | 0 | No | No |
| 18583147 | CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION | February 2024 | July 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18413653 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | January 2024 | June 2024 | Allow | 5 | 1 | 0 | No | No |
| 18513069 | CONSTRUCTION METHOD AND APPLICATION OF OVARIAN GRANULOSA CELL LINE OF ONCORHYNCHUS MYKISS | November 2023 | February 2025 | Abandon | 15 | 2 | 0 | No | No |
| 18560539 | THERAPEUTIC PHARMACEUTICAL COMPOSITION FOR BONE AND SOFT TISSUE TUMORS | November 2023 | January 2025 | Allow | 14 | 1 | 0 | Yes | No |
| 18501269 | WPRE MUTANT CONSTRUCTS, COMPOSITIONS, AND METHODS THEREOF | November 2023 | June 2024 | Allow | 7 | 0 | 0 | No | No |
| 18501837 | GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA USING GENETICALLY CORRECTED AUTOLOGOUS KERATINOCYTES | November 2023 | August 2024 | Allow | 10 | 2 | 1 | No | No |
| 18485178 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | October 2023 | May 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18474533 | Cross-Species Compatible Adeno-Associated Virus Compositions and Methods of Use Thereof | September 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18468652 | CARDIAC CELL REPROGRAMMING WITH MYOCARDIN AND ASCL1 | September 2023 | July 2024 | Allow | 10 | 1 | 1 | No | No |
| 18550503 | SMART EXOSOMES FOR ACTIVE PDAC TARGETING AND EVADING MONONUCLEAR PHAGOCYTOTIC SYSTEM | September 2023 | May 2024 | Allow | 8 | 1 | 0 | No | No |
| 18463907 | USE OF CD33CAR MODIFIED HIGH AFFINITY NK CELLS (T-HANK) TO REDUCE MYELOID-DERIVED SUPPRESSOR CELLS SUPPRESSOR ACTIVITY (OR REDUCE NEGATIVE IMPACT ON NK CELL ACTIVITY) | September 2023 | October 2024 | Allow | 13 | 1 | 1 | No | No |
| 18242731 | METHODS RELATING TO INTESTINAL ORGAN-ON-A-CHIP | September 2023 | October 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18461866 | POTENCY ASSAY | September 2023 | December 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18459302 | METHODS OF USE FOR CAR T CELLS | August 2023 | November 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18458744 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18458752 | COMPOSITIONS AND METHODS FOR TREATING NON-AGE-ASSOCIATED HEARING IMPAIRMENT IN A HUMAN SUBJECT | August 2023 | May 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18450549 | HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELL | August 2023 | June 2025 | Abandon | 22 | 3 | 1 | Yes | No |
| 18358358 | MUTATED POLYPEPTIDES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | July 2023 | November 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18339157 | METHODS AND COMPOSITIONS FOR MODULATING CAR-T ACTIVITY | June 2023 | November 2023 | Allow | 5 | 0 | 0 | No | No |
| 18203222 | NANOHELIX-SUBSTRATE COMPLEX FOR CONTROLLING MACROPHAGE BEHAVIOR, PREPARATION METHOD THEREOF, AND METHOD OF CONTROLLING ADHESION AND POLARIZATION OF MACROPHAGE BY USING THE SAME | May 2023 | August 2024 | Allow | 15 | 1 | 0 | Yes | No |
| 18320244 | Methods for Generation for Pluripotent and Multipotent Cells | May 2023 | November 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18318507 | METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES | May 2023 | January 2024 | Allow | 8 | 1 | 0 | No | No |
| 18318566 | CELLULAR REPROGRAMMING TO REVERSE AGING AND PROMOTE ORGAN AND TISSUE REGENERATION | May 2023 | July 2024 | Allow | 14 | 5 | 0 | Yes | No |
| 18309466 | ETV2 AND USES THEREOF | April 2023 | December 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18250609 | Barcoded Cells Engineered With Heterozygous Genetic Diversity | April 2023 | February 2025 | Abandon | 21 | 2 | 0 | No | No |
| 18295159 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY | April 2023 | December 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18295150 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY | April 2023 | December 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18295152 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY | April 2023 | December 2023 | Allow | 8 | 1 | 0 | Yes | No |
| 18192492 | METHODS FOR IMPROVING THE HEALTH OF PORCINE SPECIES BY TARGETED INACTIVATION OF CD163 | March 2023 | March 2025 | Allow | 24 | 2 | 0 | No | No |
| 18188854 | Method for Mosquito Control | March 2023 | September 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 18246318 | CLAUDIN 18.2 T CELL-ANTIGEN COUPLERS AND USES THEREOF | March 2023 | February 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18185656 | GENE THERAPY VECTOR WITH MINIMIZING RECOMBINATION, RECOMBINANT RETROVIRUS COMPRISING THE VECTOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING THE RECOMBINANT RETROVIRUS | March 2023 | February 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18119201 | GENE THERAPY FOR NIEMANN-PICK DISEASE TYPE A | March 2023 | June 2025 | Abandon | 27 | 1 | 0 | Yes | No |
| 18118558 | ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME | March 2023 | December 2023 | Allow | 9 | 1 | 0 | No | No |
| 18175010 | METHOD OF USING A GENETICALLY MODIFIED MOUSE THAT EXPRESSES HUMAN ALBUMIN | February 2023 | February 2025 | Allow | 23 | 2 | 0 | No | No |
| 18158173 | ENHANCED VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | January 2023 | December 2024 | Allow | 23 | 3 | 1 | No | No |
| 18157421 | PSEUDOTYPED VIRAL PARTICLES, COMPOSITIONS COMPRISING THE SAME, AND USES THEREOF | January 2023 | August 2023 | Allow | 7 | 0 | 0 | No | No |
| 18157052 | METHODS AND COMPOSITIONS FOR GENOMIC INTEGRATION | January 2023 | January 2025 | Allow | 24 | 2 | 1 | No | No |
| 18152699 | VIRAL DELIVERY OF NEOANTIGENS | January 2023 | June 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18094148 | METHODS OF MANUFACTURE OF IMMUNOCOMPATIBLE CHORIONIC MEMBRANE PRODUCTS | January 2023 | May 2024 | Allow | 17 | 1 | 0 | No | No |
| 18145996 | RNA-Guided Systems for In Vivo Gene Editing | December 2022 | April 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18085420 | METHODS AND COMPOSITIONS FOR NUCLEASE-MEDIATED TARGETED INTEGRATION OF TRANSGENES INTO MAMMALIAN LIVER CELLS | December 2022 | July 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18068376 | METHODS AND COMPOSITIONS FOR MODIFIED FACTOR IX FUSION PROTEINS | December 2022 | March 2025 | Allow | 27 | 1 | 0 | No | No |
| 18067283 | GENE THERAPY | December 2022 | April 2025 | Abandon | 28 | 1 | 0 | No | No |
| 18080811 | EXPANDABLE CELL POPULATIONS FROM BRAIN BIOPSIES OF LIVING SUBJECTS | December 2022 | November 2024 | Allow | 23 | 0 | 0 | No | No |
| 18066175 | METHODS TO PRODUCE ROD-DERIVED CONE VIABILITY FACTOR (RDCVF) | December 2022 | May 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18065580 | GENE-REGULATING COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY | December 2022 | May 2024 | Allow | 17 | 3 | 0 | Yes | No |
| 18059540 | NOVEL HYDROGEL FOR 3D TISSUE ENGINEERING | November 2022 | December 2024 | Allow | 25 | 2 | 1 | No | No |
| 17993717 | METHODS OF CYTOTOXIC GENE THERAPY TO TREAT TUMORS | November 2022 | July 2024 | Abandon | 20 | 1 | 0 | No | No |
| 18058126 | GENE THERAPY FOR TREATING FAMILIAL HYPERCHOLESTEROLEMIA | November 2022 | May 2025 | Abandon | 29 | 1 | 0 | No | No |
| 18057572 | GENE THERAPY FOR TREATING CITRULLENEMIA | November 2022 | April 2025 | Allow | 28 | 1 | 0 | No | No |
| 18051517 | Pre-conditioned mesenchymal stem cells and preparations and applications thereof | November 2022 | March 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17976062 | GENE DELIVERY SYSTEM CONTAINING RELAXIN GENE AND PHARMACEUTICAL COMPOSITION USING RELAXIN | October 2022 | April 2025 | Abandon | 29 | 1 | 0 | No | No |
| 17974123 | METHOD OF EXPANDING AND GENERATING A POPULATION OF CYTOKINE-INDUCED KILLER CELLS FROM PERIPHERAL BLOOD | October 2022 | December 2024 | Abandon | 26 | 2 | 0 | No | No |
| 17971016 | METHOD AND DEVICE FOR REMOVAL OF CIRCULATING CELL FREE DNA | October 2022 | March 2024 | Allow | 17 | 1 | 2 | No | No |
| 17963219 | PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC STROKE | October 2022 | June 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17938501 | Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof | October 2022 | April 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17938607 | USE OF EXOSOMES DERIVED FROM MESENCHYMAL STEM CELLS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS | October 2022 | March 2025 | Abandon | 30 | 1 | 0 | No | No |
| 17938314 | METHODS OF TREATING METASTATIC LESIONS AND COMPOSITIONS THEREOF | October 2022 | May 2025 | Abandon | 31 | 1 | 0 | No | No |
| 17937096 | PHARMACEUTICAL COMPOSITION CONTAINING NEPRILYSIN-OVEREXPRESSING STEM CELL, CONDITIONED MEDIUM THEREOF, AND EXOSOME ISOLATED THEREFROM AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF COGNITIVE IMPAIRMENT | September 2022 | June 2025 | Allow | 32 | 2 | 0 | No | No |
| 17956257 | Phagemid Vector | September 2022 | February 2025 | Allow | 29 | 1 | 0 | No | No |
| 17902482 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PROPHYLAXIS OF A PERFUSION DISORDER | September 2022 | April 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17929165 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | September 2022 | February 2024 | Allow | 18 | 3 | 0 | Yes | No |
| 17823186 | HUMANIZED IL-4 AND IL-4Ra ANIMALS | August 2022 | January 2025 | Allow | 29 | 1 | 0 | No | No |
| 17893052 | NEW ONCOLYTIC VIRUS PLATFORM TO TREAT CANCERS WITH MYXOMA VIRUS | August 2022 | February 2025 | Allow | 30 | 1 | 0 | No | No |
| 17820789 | ENHANCEMENT OF UMBILICAL CORD MESENCHYMAL STEM CELL THERAPEUTIC ACTIVITY BY STIMULATORS OF T REGULATORY CELLS AND/OR CELLS EXPRESSING CD73 | August 2022 | April 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17819909 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | August 2022 | March 2023 | Allow | 7 | 2 | 0 | Yes | No |
| 17819214 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | August 2022 | January 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 17819219 | RESTIMULATION OF CRYOPRESERVED TUMOR INFILTRATING LYMPHOCYTES | August 2022 | January 2024 | Allow | 18 | 2 | 0 | No | No |
| 17884360 | Composition For Treating Tauopathy In The Brain, Brain Stem and Spinal Column | August 2022 | April 2025 | Abandon | 32 | 2 | 0 | No | No |
| 17884069 | CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS | August 2022 | November 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17817772 | PHOTO-CURABLE BIOINK TO FABRICATE ULTRA-STRONG, ELECTROCONDUCTIVE, AND BIOCOMPATIBLE HYDROGEL FOR REGENERATIVE MEDICINE | August 2022 | April 2024 | Allow | 20 | 1 | 1 | No | No |
| 17879559 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | August 2022 | April 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17814791 | METHODS OF PRODUCING HUMAN FOREGUT ENDODERM CELLS EXPRESSING PDX1 FROM HUMAN DEFINITIVE ENDODERM | July 2022 | May 2024 | Abandon | 22 | 0 | 1 | No | No |
| 17871383 | METHODS AND COMPOSITIONS FOR GENERATING PACEMAKER CELLS | July 2022 | April 2025 | Abandon | 33 | 1 | 0 | No | No |
| 17814388 | GENETICALLY MODIFIED T CELL RECEPTOR MICE | July 2022 | August 2024 | Abandon | 25 | 3 | 0 | Yes | Yes |
| 17813530 | RNA-CODED ANTIBODY | July 2022 | March 2025 | Abandon | 32 | 1 | 0 | No | No |
| 17792713 | PREPARATION METHOD AND SYSTEM FOR RECOMBINANT ADENO-ASSOCIATED VIRUS, AND RECOMBINANT BACMID | July 2022 | March 2025 | Allow | 32 | 2 | 0 | No | No |
| 17865292 | BLOCKADE OF CD7 EXPRESSION AND CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY OF T-CELL MALIGNANCIES | July 2022 | December 2023 | Allow | 17 | 2 | 1 | Yes | No |
| 17812425 | VECTOR AND METHOD FOR TREATING BIETTI'S CRYSTALLINE DYSTROPHY | July 2022 | April 2024 | Allow | 22 | 3 | 0 | No | No |
| 17812342 | VIABLE GENETICALLY MODIFIED SHEEP WITH AN INACTIVATED ALPHA-1,3-GALACTOSYLTRANSFERASE (GGTA1) GENE | July 2022 | January 2025 | Allow | 31 | 4 | 1 | No | No |
| 17862797 | METHODS FOR ENHANCING EFFICACY OF THERAPEUTIC IMMUNE CELLS | July 2022 | May 2025 | Allow | 34 | 1 | 0 | Yes | No |
| 17862666 | RAPID ASSAY FOR DETECTION OF SARS-CoV-2 ANTIBODIES | July 2022 | December 2024 | Allow | 29 | 1 | 0 | No | No |
| 17811089 | NUCLEIC ACIDS COMPRISING A MODIFIED RODENT ACTIVIN A RECEPTOR TYPE 1 (ACVR1) GENE | July 2022 | May 2024 | Allow | 22 | 1 | 0 | No | No |
| 17857495 | MESENCHYMAL STEM CELLS FOR USE IN THE TREATMENT OF ATOPIC DERMATITIS | July 2022 | March 2025 | Allow | 32 | 3 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1638.
With a 38.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 36.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Art Unit 1638 is part of Group 1630 in Technology Center 1600. This art unit has examined 12,846 patent applications in our dataset, with an overall allowance rate of 76.9%. Applications typically reach final disposition in approximately 29 months.
Art Unit 1638's allowance rate of 76.9% places it in the 47% percentile among all USPTO art units. This art unit has a below-average allowance rate compared to other art units.
Applications in Art Unit 1638 receive an average of 1.42 office actions before reaching final disposition (in the 20% percentile). The median prosecution time is 29 months (in the 47% percentile).
When prosecuting applications in this art unit, consider the following:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.